Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped down prior to trading on Thursday . The stock had previously closed at $8.6720, but opened at $8.33. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.33, with a volume of 415 shares trading hands.

Analyst Upgrades and Downgrades

SGIOY has been the topic of several analyst reports. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 4.1%

The company has a quick ratio of 1.46, a current ratio of 1.58 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $9.38 and a 200-day simple moving average of $9.90. The company has a market cap of $14.20 billion, a PE ratio of 10.43, a P/E/G ratio of 3.32 and a beta of 0.08.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. The business had revenue of $881.71 million during the quarter, compared to analysts’ expectations of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%. Equities research analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.